1
|
Dinesh K, White N, Baker L, Sowden JE, Behrens-Spraggins S, Wood E, Charles J, Herrmann DN, Sharma G, Eichinger K. Disease-specific wearable sensor algorithms for profiling activity, gait, and balance in individuals with Charcot-Marie-Tooth disease type 1A. J Peripher Nerv Syst 2023; 28:368-381. [PMID: 37209301 DOI: 10.1111/jns.12562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 05/05/2023] [Accepted: 05/15/2023] [Indexed: 05/22/2023]
Abstract
BACKGROUND/AIMS Charcot-Marie-Tooth Disease type 1A (CMT1A), the most common inherited peripheral neuropathy, is characterized by progressive sensory loss and weakness, which results in impaired mobility. Increased understanding of the genetics and pathophysiology of CMT1A has led to development of potential therapeutic agents, necessitating clinical trial readiness. Wearable sensors may provide useful outcome measures for future trials. METHODS Individuals with CMT1A and unaffected controls were recruited for this 12-month study. Participants wore sensors for in-clinic assessments and at-home, from which activity, gait, and balance metrics were derived. Mann-Whitney U tests were used to analyze group differences for activity, gait, and balance parameters. Test-retest reliability of gait and balance parameters and correlations of these parameters with clinical outcome assessments (COAs) were examined. RESULTS Thirty individuals, 15 CMT1A, and 15 controls, participated. Gait and balance metrics demonstrated moderate to excellent reliability. CMT1A participants had longer step durations (p < .001), shorter step lengths (p = .03), slower gait speeds (p < .001), and greater postural sway (p < .001) than healthy controls. Moderate correlations were found between CMT-Functional Outcome Measure and step length (r = -0.59; p = .02), and gait speed (r = 0.64; p = .01); 11 out of 15 CMT1A participants demonstrated significant increases in stride duration between the first and last quarter of the 6-min walk test, suggesting fatigue. INTERPRETATION In this initial study, gait and balance metrics derived from wearable sensors were reliable and associated with COAs in individuals with CMT1A. Larger longitudinal studies are needed to confirm our findings and evaluate sensitivity and utility of these disease-specific algorithms for clinical trial use.
Collapse
Affiliation(s)
- K Dinesh
- Department of Electrical and Computer Engineering, University of Rochester, Rochester, New York, USA
| | - N White
- Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
| | - L Baker
- Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
| | - J E Sowden
- Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
| | - S Behrens-Spraggins
- Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
| | - E Wood
- Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
| | - J Charles
- Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
| | - D N Herrmann
- Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
| | - G Sharma
- Department of Electrical and Computer Engineering, University of Rochester, Rochester, New York, USA
| | - K Eichinger
- Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
| |
Collapse
|
2
|
de Valle K, Dobson F, Woodcock I, Carroll K, Ryan MM, Heatwole C, Eichinger K, McGinley JL. Reliability and validity of the FSHD-composite outcome measure in childhood facioscapulohumeral dystrophy. Neuromuscul Disord 2021; 31:706-715. [PMID: 34210539 DOI: 10.1016/j.nmd.2021.05.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 05/09/2021] [Accepted: 05/26/2021] [Indexed: 11/25/2022]
Abstract
This study aims to investigate intra-rater reliability and construct validity of the Facioscapulohumeral Dystrophy Composite Outcome Measure (FSHD-COM), in childhood FSHD. Participants included eighteen children with FSHD, and matched healthy controls. Reliability data were collected from 15 participants with FSHD over two testing sessions. Validity data were collected from all participants. Participants with FSHD completed; the FSHD-COM (and modified pediatric version), Motor Function Measure-32 (MFM-32), FSHD Severity Scales, Performance of the Upper Limb 2.0, Pediatric Quality of Life™ Neuromuscular Module and pediatric FSHD Health-Index Questionnaire. Both versions of the FSHD-COM showed excellent intra-rater reliability (ICC1,2 > 0.99, lower 95%CI > 0.98) with a Minimal Detectable Change (MDC95%) of ≤14.5%. The FSHD-COM had robust and widespread correlations with other related outcome measures. The FSHD-COM versions and 6 min walk test effectively discriminated between children with and without FSHD; the MFM-32 and 10 m walk/run test did not. Ceiling effects were not observed on either version of the FSHD-COM. Reliability and validity findings in this childhood FSHD study concord with estimates in adults. Both versions of the FSHD-COM were effective in discriminating disease in children with mild FSHD symptoms. The FSHD-COM has the potential to be a useful measure of function across the life span.
Collapse
Affiliation(s)
- K de Valle
- Department of Neurology, The Royal Children's Hospital, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia; Department of Physiotherapy, The University of Melbourne, Australia.
| | - F Dobson
- Department of Physiotherapy, The University of Melbourne, Australia
| | - I Woodcock
- Department of Neurology, The Royal Children's Hospital, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Australia
| | - K Carroll
- Department of Neurology, The Royal Children's Hospital, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia
| | - M M Ryan
- Department of Neurology, The Royal Children's Hospital, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Australia
| | - C Heatwole
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA; Center for Health and Technology, Outcomes Division, University of Rochester Medical Center, Rochester, NY, USA
| | - K Eichinger
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
| | - J L McGinley
- Department of Physiotherapy, The University of Melbourne, Australia
| |
Collapse
|
3
|
Shaw D, Faino A, Statland J, Eichinger K, Tapscott S, Tawil R, Friedman S, Wang L. FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Mongiovi P, Meyers S, Griggs R, Eichinger K, Ciafaloni E. MYASTHENIA & RELATED DISORDERS. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
Statland J, Eichinger K, Currence M, McIntyre M, Johnson N, Tawil R. P.45Patterns of muscle involvement, predictive characteristics, and meaningful change for functional motor tasks in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
LoRusso S, Johnson N, McDermott M, Eichinger K, Butterfield R, Higgs K, Lewis L, Mul K, Van Engelen B, Sacconi S, Sansone V, Carraro E, Shieh P, Wagner K, Wang L, Statland J, Tawil R, the ReSolve Investigators. P.46Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, multi-center prospective study. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Eichinger K, Dilek N, Dekdebrun J, Martens W, Heatwole C, Thornton C, Moxley R, Pandya S. P.18.3 Test–retest reliability of strength measurements of the long finger flexors (LFF) in patients with myotonic dystrophy type 1. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Pandya S, Caspers K, Eichinger K, Mathews K, Romitti P. P.7.6 Needs of caregivers/families affected by Duchenne and Becker Muscular Dystrophy (DBMD): Data from the Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet). Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Eichinger K, Dilek N, Dekdebrun J, Martens W, Heatwole C, Thornton C, Moxley R, Pandya S. Relationships between Upper Extremity Strength and the Purdue Pegboard Test and the Jebsen-Taylor Hand Function Test in Patients with Myotonic Dystrophy Type 1 (P05.187). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p05.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
10
|
Pandya S, Eichinger K, Dilek N, Dekdebrun J, Martens W, Heatwole C, Thornton C, Moxley R. Correlation between Biomarkers and Surrogate Markers in Patients with Myotonic Dystrophy Type 1 (DM-1): Data from the Study of Pathogenesis and Progression in DM (STOPP DM) (P05.185). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p05.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Pandya S, Eichinger K, Dilek N, Dekdebrun J, Martens W, Heatwole C, Thornton C, Moxley R. Symptoms of Myotonia as Reported by Patients with Myotonic Dystrophy Type 1: Location, Description and Severity- Implications for Clinical Trials (P05.184). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p05.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
12
|
Schelling G, Briegel J, Eichinger K, Raum W, Forst H. Pulmonary artery catheter placement and temporary cardiac pacing in a patient with a persistent left superior vena cava. Intensive Care Med 1991; 17:507-8. [PMID: 1797901 DOI: 10.1007/bf01690781] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
13
|
|
14
|
Kienzl E, Eichinger K, Sofic E, Jellinger K, Riederer P, Kuhn W, Fuchs G, Laux G. Urinary dopamine sulfate: regulations and significance in neurological disorders. J Neural Transm Suppl 1990; 32:471-9. [PMID: 2089110 DOI: 10.1007/978-3-7091-9113-2_64] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Dopamine-3-O-sulfate (DA-3-O-S) and dopamine-4-O-sulfate (DA-4-O-S) are important end products of L-dopa metabolism. Therefore they may give indications of disturbances in the peripheral metabolism of catecholamines, when measured in urine samples of patients with Parkinson's disease (PD). In addition, information about the reliability of DA sulfatation after L-dopa therapy may be of significance for its role in the elimination of DA from the peripheral nervous system. Although DA-3-O-S appears to be the predominant sulfo-conjugate in urine, there are no changes in PD nor in depression syndrome compared to controls with or without other neurological disorders. By contrast, DA-4-O-S is significantly decreased in de novo PD subjects. However, a similar reduction is notable in patients with other neurological disorders. In depressed persons the loss of this compound was less pronounced as compared to de novo PD. Treatment with combined L-dopa therapy caused increased excretion of DA-3-O-S, while changes in DA-4-O-S were only marginal. It is concluded that urinary DA-3-O-S cannot be used as marker for PD, while DA-4-O-S is significantly reduced in a variety of neurological disorders and in particular in de novo PD. Further studies are necessary to elucidate its role as possible peripheral marker to distinguish preclinical PD and depression syndrome.
Collapse
Affiliation(s)
- E Kienzl
- Ludwig Boltzmann Institute of Clinical Neurobiology, Lainz-Hospital, Vienna, Austria
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Kienzl E, Eichinger K. Preparation of dopamine 3-O-sulphate and dopamine 4-O-sulphate as reference substances and high-performance liquid chromatographic trace determination. J Chromatogr 1988; 430:263-9. [PMID: 3235502 DOI: 10.1016/s0378-4347(00)83161-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Simple syntheses of the biologically important but hitherto difficult to obtain dopamine sulpho conjugates dopamine 3-O-sulphate (I) and dopamine 4-O-sulphate (II), as analytical reference substances, starting from dopamine hydrochloride are described. A method for the determination of I and II with reversed-phase high-performance liquid chromatographic separation and coulometric detection in human urine together with calibration and current-voltage curves are presented. Detection limits of approximately 100 pg of I or II and unequivocal substance identifications even in very complex substrates such as human urine are reported.
Collapse
Affiliation(s)
- E Kienzl
- Ludwig Boltzmann-Institute of Clinical Neurobiology, Vienna, Austria
| | | |
Collapse
|
16
|
Haas RJ, Belohradsky B, Dickerhoff R, Eichinger K, Eife R, Holtmann H, Goetz O, Graubner U, Peller P. [Active chickenpox vaccination of children with acute leukemia or other neoplastic diseases]. Klin Padiatr 1985; 197:477-80. [PMID: 3003449 DOI: 10.1055/s-2008-1034025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
26 patients with acute leukemia and other malignancies susceptible to varicella were vaccinated during maintenance chemotherapy. Vaccination was done with OKA strain of live attenuated varicella vaccine developed by Takahashi 1974. All recipients showed no adverse clinical reactions. There was no spread of vaccine virus to others. Seroconversion was 94% in seronegative patients. In those having low antibody titers before vaccination in 56% booster effect was demonstrable. None of the seroconverted recipients contracted varicella in spite of documented contact exposure. Vaccine zoster was not observed. The results suggest that in immunocompromised children live varicella vaccination has a protective effect against varicella infection which has a described mortality rate up 7% in this patients.
Collapse
|
17
|
|
18
|
Berbalk H, Eichinger K, Schuster R. Correlations between chemical structure and k-value in the TLC of epimeric 3-ethinyl-3-cholestanoles. ACTA ACUST UNITED AC 1979. [DOI: 10.1002/jhrc.1240020812] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
19
|
Berbalk H, Pieh G, Eichinger K. Untersuchungen �ber die zusammensetzung der unverseifbaren Bestandteile in Fetts�uredestillaten aus Tall�l. Monatshefte f�r Chemie 1975. [DOI: 10.1007/bf00900861] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Hromatka O, Binder D, Eichinger K. �ber die Synthese von 5-(o-Chlorphenyl)-7-trifluormethyl-1Hthieno[3,2?e]-1,4-diazepin-2(3H)-on. Monatshefte f�r Chemie 1974. [DOI: 10.1007/bf00911298] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
21
|
Hromatka O, Binder D, Eichinger K. �ber die Synthese von substituierten Thieno[3,4?b]chinolin-9(4H)-onen. Monatshefte f�r Chemie 1974. [DOI: 10.1007/bf00909849] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
22
|
Hromatka O, Binder D, Eichinger K. �ber den Mechanismus derDieckmann-Reaktion von 3-(Methoxycarbonylmethylthio)-propions�uremethylester. Monatshefte f�r Chemie 1973. [DOI: 10.1007/bf00909636] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Hromatka O, Binder D, Eichinger K. �ber die Synthese von 5-Phenyl-1H-thieno[3,4?e]1,4-diazepin-2(3H)-on. Monatshefte f�r Chemie 1973. [DOI: 10.1007/bf00909635] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Hromatka O, Binder D, Eichinger K. �ber Synthese und Strukturbeweis von substituierten 5-Phenyl-1H-thieno[3,4?e]1,4-diazepin-2(3H)-onen. Monatshefte f�r Chemie 1973. [DOI: 10.1007/bf00909646] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Hromatka O, Sengstschmid G, Eichinger K. Thebain?Maleinimid-und Thebain?N-substituierte Maleinimid-Addukte. Monatshefte f�r Chemie 1971. [DOI: 10.1007/bf00909927] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|